Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.

MLA

Wang, Mengna, et al. “Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Canadian Journal of Diabetes, vol. 48, no. 6, Aug. 2024, p. 364. EBSCOhost, https://doi.org/10.1016/j.jcjd.2024.04.009.

APA

Wang, M., Li, M., Wang, L., Wang, F., Cao, X., Li, S., & Zheng, Z. (2024). Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Canadian Journal of Diabetes, 48(6), 364. https://doi.org/10.1016/j.jcjd.2024.04.009

Chicago

Wang, Mengna, Ming Li, Libin Wang, Fang Wang, Xulin Cao, Shengyou Li, and Zhichang Zheng. 2024. “Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Canadian Journal of Diabetes 48 (6): 364. doi:10.1016/j.jcjd.2024.04.009.